Last reviewed · How we verify
NCT02906657: CONCIPAGE
Medication Reconciliation Using Electronic Pharmaceutical Record: A Multicenter Study in the Hospitalized Elderly
NA trial testing Medication reconciliation in Adverse Drug Event in 2,000 participants. Completed in 10 January 2019.
10 January 2019
Quick facts
| Lead sponsor | Assistance Publique - Hôpitaux de Paris |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | health services research |
| Enrollment | 2,000 |
| Start date | 3 November 2016 |
| Primary completion | 10 January 2019 |
| Estimated completion | 10 January 2019 |
| Sites | 1 location across France |
Drugs / interventions tested
- Medication reconciliation
Conditions studied
- Adverse Drug Event — all drugs for Adverse Drug Event →
Sponsor
Assistance Publique - Hôpitaux de Paris — full company profile →
Who can join
65 and older, any sex, with Adverse Drug Event. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Context Adverse drug events (ADEs) may occur in hospitalized patients and may result from discrepancies between patient's current medications and the drugs prescribed at admission (omission,, dosing errors….). Consequences of these discrepancies may be mild (e.g. isolated biological abnormalities), but may also lead to severe clinical outcomes. Medication reconciliation is a process of creating the most accurate list of patient's current medication in order to decrease discrepancies and eventually ADEs. Information technology and electronic health records are of great interest in this process. In France, medications dispensed in community pharmacies during the past 4 months are registered in a patient's electronic pharmaceutical record. The impact of this record, together with pharmacist medication reconciliation, will be tested in the CONCIPAGE study. Design The CONCIPAGE study is a national, multicenter, cluster-randomized, two-period cross-over study. It will estimate the impact of medication reconciliation, made by a pharmacist, using the patient pharmaceutical record, on the occurrence of ADEs during the hospitalization of patients aged 65 years and over.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02906657
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Medication reconciliation
Trials testing the same drug.
- NCT05167578 — Identifying Reasons for Non-adherence in Patients With Multi-morbidity · unknown
- NCT04744584 — Medication Reconciliation in Pulmonary Hypertension · completed
- NCT04358874 — Maximizing Acute Kidney Injury End-point Intervention Post-Discharge (MAKE-IT) Study · NA · completed
- NCT03654963 — Study to Assess the Impact of Medication Reconciliation at Hospital Admission on Healthcare Outcomes · NA · completed
- NCT03955965 — Medication Reconciliation in an Emergency Department: How to Prioritize Patients ? · completed
Other recruiting trials for Adverse Drug Event
Currently open trials in the same condition.
- NCT06575530 — Sedation Efficacy and Safety of Remazolam Besylate in Ventilated Surgical Critically Ill Patients · Phase 4 · recruiting
- NCT06498167 — Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib) · recruiting
- NCT07164300 — Comparative Study of Tranexamic Acid Dosing in Cardiac Surgery · NA · recruiting
- NCT05084196 — Melatonin for Prevention of Kidney Injury · Phase 3 · recruiting
- NCT05717712 — Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma · Phase 1 · recruiting
Other Assistance Publique - Hôpitaux de Paris trials
Trials by the same sponsor.
- NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
- NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
- NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
- NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
- NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02906657 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
- Last refreshed: 6 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02906657.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing